Promacta Market Report 2026

Promacta Market Overview

• Promacta market size has reached to $4.11 billion in 2025 • Expected to grow to $6.1 billion in 2030 at a compound annual growth rate (CAGR) of 8.1% • Growth Driver: Rising Prevalence of Aplastic Anemia Driving Growth Of The Market • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Promacta Market?

Promacta (eltrombopag) is an oral thrombopoietin receptor agonist (TPO-RA) used to increase platelet production in patients with certain blood disorders. It is primarily prescribed for conditions where the body does not produce enough platelets, increasing the risk of bleeding. Promacta helps reduce the risk of bleeding in patients with low platelet counts. The main types of indications of promacta are chronic immune thrombocytopenia, severe aplastic anemia, hepatitis C-associated thrombocytopenia, and others. Chronic immune thrombocytopenia (ITP) is a long-term autoimmune disorder causing low platelets, leading to excessive bleeding and requiring treatment to suppress immunity or boost platelet production. It is available in different dosage forms, such as tablets and oral suspension, and distributed through various distribution channels, including hospital pharmacies, retail pharmacies, and online pharmacies.

What Is The Promacta Market Growth Forecast?

The promacta market size is expected to see strong growth in the next few years. It will grow to $6.1 billion in 2030 at a compound annual growth rate (CAGR) of 8.1%. The growth in the forecast period can be attributed to expansion of personalized hematology treatments, rising focus on rare blood disorder management, growing adoption of long-term outpatient therapies, increasing investments in hematology drug innovation, broader access to advanced thrombopoietin therapies. Major trends in the forecast period include increasing adoption of targeted thrombopoietin receptor therapies, rising focus on personalized treatment for thrombocytopenia, growing demand for oral platelet-stimulating drugs, expansion of indication-specific treatment protocols, enhanced emphasis on long-term patient management.

Global Promacta Market Segmentation

1) By Indication: Chronic Immune Thrombocytopenia, Severe Aplastic Anemia, Hepatitis C-associated Thrombocytopenia, Other Indications 2) By Dosage Form: Tablets, Oral Suspension 3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies Subsegments: 1) By Chronic Immune Thrombocytopenia (ITP): Primary Immune Thrombocytopenia, Secondary Immune Thrombocytopenia 2) By Severe Aplastic Anemia: Adult Severe Aplastic Anemia, Pediatric Severe Aplastic Anemia 3) By Hepatitis C-associated Thrombocytopenia: Genotype 1 Hepatitis C-associated Thrombocytopenia, Genotype 2 Hepatitis C-associated Thrombocytopenia, Genotype 3 Hepatitis C-associated Thrombocytopenia 4) By Other Indications: Myelodysplastic Syndromes (MDS), Bone Marrow Disorders, Radiation-Induced Thrombocytopenia

What Are The Drivers Of The Promacta Market?

The increasing prevalence of aplastic anemia is expected to propel the growth of the promacta market going forward. Aplastic anemia is a rare disorder in which the bone marrow fails to generate sufficient blood cells, causing fatigue, infections, and an increased risk of bleeding. The prevalence of aplastic anemia is due to exposure to toxic chemicals, certain medications, viral infections, autoimmune disorders, and genetic predisposition. Promacta stimulates bone marrow stem cells to produce blood cells, increasing counts of platelets, red blood cells, and neutrophils. It reduces the need for transfusions and decreases the risk of bleeding and infections in patients with aplastic anemia. For instance, in April 2024, according to the Anthony Nolan, a UK-based charity that works in leukemia and hematopoietic stem cell transplantation, approximately 100 to 150 people diagnosed with aplastic anemia in the UK annually. Therefore, the increasing prevalence of aplastic anemia is driving the growth of the promacta industry. The rise in healthcare expenditure is expected to propel the growth of the Promacta market going forward. Healthcare expenditure is the overall cost of medical services, treatments, and infrastructure to preserve and enhance public and individual health. The rise in healthcare expenditure is driven by factors such as an aging population, advancements in medical technology, and increased health insurance coverage. The rise in healthcare expenditure enhances patient access to advanced treatments for thrombocytopenia and other blood disorders. It also improves diagnostic capabilities, facilitating early detection and increased adoption of PROMACTA. For instance, in May 2024, according to a report published by the Office for National Statistics, a UK-based government department, total healthcare expenditure increased by 5.6% in nominal terms in 2023. UK healthcare expenditure was around £292 ($338.58) billion in 2023; these are based on more timely but less comprehensive data sources than preceding years. Therefore, the rise in healthcare expenditure is driving the growth of the Promacta industry. The increasing geriatric population is expected to propel the growth of the promacta market going forward. The geriatric population comprises individuals aged 65 and above, often needing specialized care and support for age-related health concerns. The increasing geriatric population is due to rising life expectancy, improved healthcare, declining birth rates, and advancements in medical treatments. Promacta supports the geriatric population by boosting platelet production in blood disorders, reducing bleeding risks, strengthening immune function, and improving treatment outcomes, especially in older adults prone to platelet deficiencies. For instance, in January 2024, according to the Population Reference Bureau, a Kenya-based nonprofit organization, the population of Americans aged 65 and older is expected to grow from 58 million in 2022 to 82 million by 2050. Therefore, the increasing geriatric population is driving the growth of the promacta industry.

Key Players In The Global Promacta Market

Major companies operating in the promacta market are Novartis AG, Amgen Inc, Pfizer Inc, Takeda Pharmaceutical Company Limited, Bristol Myers Squibb Company, Roche Holding AG, Sanofi SA, AbbVie Inc, AstraZeneca plc, GlaxoSmithKline plc, Merck And Co Inc, Johnson And Johnson, CSL Behring, Grifols SA, Octapharma AG, Kedrion Biopharma, ADMA Biologics Inc, Bio Products Laboratory Ltd, Apotex Inc, Teva Pharmaceutical Industries Ltd, Sandoz International GmbH, Dr Reddys Laboratories Ltd

Regional Outlook

North America was the largest region in the promacta market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Promacta Market?

The promacta market consists of sales of extended-release tablets and powder for suspension. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Promacta Market Report 2026?

The promacta market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the promacta industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.